/Clinical Trial

Theranos, the FDA, and the Laboratory-Developed Test (LDT) loophole

By |2019-02-13T16:57:06-07:00February 13th, 2019|

Cover of Forbes 400 Sept 2015 issue: "The Freshman: Elizabeth Holmes leads the class of 2014" Theranos, the FDA, and the Laboratory-Developed Test (LDT) loophole How could Theranos get away with fraud for such a long time? The American television news broadcaster ABC has produced an excellent six-part audio podcast called “The Dropout” [...]

Why isn’t cancer prevention a higher priority?

By |2019-01-28T14:24:34-07:00November 5th, 2018|

Why isn't cancer prevention a higher priority? Cancer death rates could be drastically reduced Cancer is the second leading cause of death worldwide. In a recent issue of the journal Science (Sept 28 2018, Vol 361 Issue 6409 page 1317, "Cancer Prevention: Molecular and epidemiologic consensus" Song M and Tomasetti C et al. ref 1) [...]

The Challenges and Opportunities of Prospective Longitudinal Studies

By |2019-01-28T14:45:51-07:00October 24th, 2018|

The Challenges and Opportunities of Prospective Longitudinal Studies Is it possible to accelerate the future? What is exciting about working in the field of clinical molecular diagnostics is its promise of real impact on human health. Yet the path from biomarker discovery to an FDA-approved test in general use is a long and painstaking process: [...]

Good things come to those who sign up for
An Early Mark
Join our email list to get the latest blog posts straight to your inbox
SUBSCRIBE
Give it a try, you can unsubscribe anytime.
close-link